Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
An analysis looked at the way HIV rebounds during treatment interruptions based on the age of the antiretrovirals used.
This raises concerns that men with HIV participating in cure and therapeutic vaccine studies may transmit the virus.
A new study found that 44% of Medicaid enrollees with HIV who stopped antiretroviral treatment did not restart therapy within 18 months.
According to a survey, many people with HIV don’t understand how cure trials work.
A new study found that 44% of such individuals who stopped antiretroviral treatment did not restart therapy within 18 months.
Previous research has shown that long interruptions are not safe—but what about shorter, more closely monitored gaps in treatment?
Many HIV cure trials take participants off antiretrovirals for a period in order to see how well the investigational treatment works.
This raises the risk of transmitting the virus while interrupting treatment as part of a study.
Post-HIV-treatment viral control is more likely in those treated very early.
Periodic infusions of such antibodies may eventually become a new way of treating the virus.
This is according to an analysis of pooled data from various studies looking at those who controlled HIV after stopping treatment.
Cure studies typically require a temporary break in HIV treatment, often with little promise of a personal benefit to the participant.
A considerable proportion of HIV transmissions take place when someone has recently contracted the virus or has interrupted ARV treatment.
A considerable proportion of HIV transmissions occur when someone is newly infected with the virus or has interrupted antiretroviral treatment...
Many HIV-positive people cycle in and out of care for the virus, signaling a need for ongoing measures to keep them integrated into the health...
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.